The Genentech partnership provides a major non-dilutive capital infusion and platform validation, but AL050 is preclinical with no near-term revenue. Watch for the October 13 R&D webinar on wholly owned pipeline programs (AL137, AL164, AL062) and the Q1 2027 IND target for AL037/AL137.
Price Chart
Executive Summary
Alector entered an exclusive global license agreement with Genentech for its AL050 GCase enzyme replacement therapy program, receiving a $100M upfront payment with up to $1.17B in milestones plus tiered royalties. The deal extends cash runway into 2029 and validates Alector's ABC blood-brain barrier platform, while the company also exercised an option to license related patents from Spur Therapeutics for a $15M payment. Preliminary Q3 cash of $138.7M (pro forma $223.7M after deal payments) was disclosed.
Key Financial Metrics
Key Facts
- Alector granted Genentech exclusive worldwide rights to develop and commercialize AL050, a brain-penetrant GCase ERT for Parkinson's disease
- Alector receives $100M upfront from Genentech, with potential for up to $1.17B in development, regulatory, and commercial milestone payments
- Alector eligible for tiered royalties on net sales of GCase candidates at rates from single-digit to double-digit percentages
- Alector retains ownership of ABC platform and full rights to apply it across wholly owned pipeline outside of GCases
- Alector exercised option to license GCase-related patents from Spur Therapeutics for $15M payment plus percentage of milestones and royalties from Genentech sublicense
- Preliminary cash, cash equivalents, and marketable securities of $138.7M as of Sep 30, 2026; pro forma $223.7M after deal payments, funding operations into 2029
- Genentech responsible for all development, regulatory, manufacturing, and commercialization of GCase candidates
- AL050 is preclinical; Genentech partnership moves it toward the clinic
Financial Impact
$100M upfront payment plus up to $1.17B in milestones and tiered royalties; pro forma cash of $223.7M extends runway into 2029
Risk Factors
- AL050 is preclinical; Genentech may terminate for convenience at any time
- Milestone payments are contingent on development, regulatory, and commercial success — none guaranteed
- Spur Therapeutics sublicense creates ongoing royalty obligations on Genentech payments
- PROGRESS-AD Phase 2 trial of nivisnebart was discontinued after futility analysis
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-413090 |
| Document: alec-ex99_01.htm | 0001193125-26-413090 |
| Document: 0001193125-26-413090-index-headers.html | 0001193125-26-413090 |
| Document: 0001193125-26-413090-index.html | 0001193125-26-413090 |
| Document: 0001193125-26-413090.txt | 0001193125-26-413090 |
| 8-K Data (Synthetic) | 0001193125-26-413090 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | SC 13G | $1.82 | awaiting T+60 | — | $1.83 (+0.55%) |
Oct 23, 2026 3d ago | SC 13G | $1.84 | awaiting T+60 | — | $1.83 (−0.33%) |
Oct 16, 2026 10d ago | 424B5 | $1.95 | awaiting T+60 | — | $1.83 (+6.15%) |
Oct 16, 2026 10d ago | 8-K | $1.95 | awaiting T+60 | — | $1.83 (+6.15%) |
Oct 14, 2026 12d ago | 8-K | $1.88 | awaiting T+60 | — | $1.83 (−2.66%) |
Oct 5, 2026 22d ago | 8-K | $1.99 | awaiting T+60 | — | $1.83 (−8.04%) |
Oct 5, 2026 22d ago | Press Release | $1.99 | awaiting T+60 | — | $1.83 (−8.04%) |
Sep 18, 2026 5w ago | SC 13G | $1.93 | awaiting T+60 | — | $1.83 (−5.18%) |
Sep 4, 2026 7w ago | Insider Cluster | $2.47 | awaiting T+60 | — | $1.83 (−25.91%) |
Aug 15, 2026 10w ago | Institutional Cluster | $2.05 | awaiting T+60 | — | $1.83 (−10.73%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers